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Abstract 35 
 36 
The concept of twin-screw melt granulation (TSMG) has steadily (re)-gained interest in 37 
pharmaceutical formulation development as an intermediate step during tablet manufacturing. 38 
However, to be considered as a viable processing option for solid oral dosage forms there is a 39 
need to understand all critical sources of variability which could affect this granulation 40 
technique. The purpose of this study was to provide an in-depth analysis of the continuous 41 
TSMG process in order to expose the critical process parameters (CPP) and elucidate the 42 
impact of process and formulation parameters on the critical quality attributes (CQA) of 43 
granules and tablets during continuous TSMG. A first part of the study dealt with the screening 44 
of various amorphous polymers as binder for producing high-dosed melt granules of two model 45 
drug (i.e. acetaminophen and hydrochlorothiazide). The second part of this study described a 46 
quality-by-design (QbD) approach for melt granulation of hydrochlorothiazide in order to 47 
thoroughly evaluate TSMG, milling and tableting stage of the continuous TSMG line.  Using 48 
amorphous polymeric binders resulted in melt granules with high milling efficiency due to their 49 
brittle behaviour without producing excessive amounts of fines, providing high granule yields 50 
with low friability. Therefore, it makes them extremely suitable for further downstream 51 
processing. One of the most important CPP during TSMG with polymeric binders was the 52 
granulation-torque, which - in case of polymers with high Tg - increased during longer 53 
granulation runs to critical levels endangering the continuous process flow. However, by 54 
optimizing both screw speed and throughput or changing to polymeric binders with lower Tg it 55 
was possible to significantly reduce this risk. This research paper highlighted that TSMG must 56 
be considered as a viable option during formulation development of solid oral dosage forms 57 
based on the robustness of the CQA of both melt granules and tablets.  58 
 59 
 60 
Keywords: continuous manufacturing, twin-screw melt granulation, polymeric binders, 61 
tableting, quality by design, multivariate data analysis.  62 
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1.    INTRODUCTION 63 
 64 
Downstream processing of a drug compound into tablets is often the preferred choice during 65 
formulation development as it combines a high economic efficiency with good patient 66 
compliance. This is clearly reflected in the number of oral solid dosage forms reaching the 67 
market, for which over 70% are tablets (Patel et al., 2006). Direct compression (DC) of a 68 
formulation is intuitively the preferred tablet manufacturing route based on its simplicity and 69 
cost efficiency, however the powder mixture requires specific properties (e.g. high flowability, 70 
low segregation tendency and high compactibility) which are often lacking (Patel et al., 2006). 71 
The addition of directly compressible excipients may overcome some of these problems and 72 
yield satisfactory tablets for such materials. However, these products are often relatively 73 
expensive. Moreover, in case of high-dose formulated DC-mixtures (e.g. acetaminophen) this 74 
may lead to very large tablets, hampering the patient compliance (Gohel et al., 2005). 75 
Regarding low-dose formulations, DC is challenging since poorly flowing and cohesive drugs 76 
need to be uniformly dispersed in a powder blend to guarantee an acceptable tablet content 77 
uniformity (Bi et al., 2011). Considering the possible drawbacks of DC, pharmaceutical 78 
companies often implement granulation as a pre-treatment step in the tablet manufacturing 79 
route in order to reduce the risk of final product failure.  80 
Granulation is a well-established pharmaceutical processing technique to agglomerate primary 81 
drug and excipient particles into larger secondary particles (granules) which meet the required 82 
properties (e.g. flowability, compactibility and content uniformity) for processing into a final 83 
dosage form (Dhenge et al., 2013; Liu et al., 2017; Van Melkebeke et al., 2008; Vercruysse et 84 
al., 2015). A variety of both wet- and dry granulation techniques are used in the pharmaceutical 85 
field and have been reviewed where twin-screw wet granulation is most prominently 86 
investigated during the last decade especially in the context of continuous granulation 87 
(Fonteyne et al., 2011; Vervaet and Remon, 2009). However, some pharmaceuticals 88 
experience stability and degradation issues by wet processing and proper control of the drying-89 
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step is critical during continuous twin-screw wet granulation (TSWG) to avoid flow and 90 
compression issues (Lakshman et al., 2011).  91 
Twin-screw melt granulation (TSMG) can counter some of the wet-granulation drawbacks 92 
since the agglomeration is initiated by a softened or molten binder instead of a granulation 93 
liquid, making TSMG extremely suitable for moisture-sensitive drugs (Kowalski et al., 2009). 94 
Lakshman et al. evaluated various granulation techniques for the development of a robust 95 
manufacturing process for high-dose metformin HCL whereby TSMG was the most suitable 96 
technique. Enhanced tableting properties of the poorly compactible high-dosed drug were 97 
noticed whereas highly reproducible low moisture levels of the granules ensured end product 98 
stability and quality (Lakshman et al., 2011). Moreover, the technology enabled to reduce both 99 
process time and energy consumption since no additional drying-step is needed after 100 
granulation compared to TSWG (Monteyne et al., 2016a). This makes TSMG extremely 101 
interesting in the context of continuous manufacturing and therefore the technique steadily 102 
regained interest of research groups and industry (Batra et al., 2017; Kidokoro et al., 2002; 103 
Monteyne et al., 2016b; Mu and Thompson, 2012). Continuous processing is currently a main 104 
focus in pharmaceutical manufacturing to accelerate the transition towards more robust and 105 
efficient processes, reducing development and manufacturing costs and eventually increase 106 
the quality of the end product (Plumb, 2005; Schaber et al., 2011).  107 
The aim of this research paper was to establish a continuous TSMG concept using a twin-108 
screw extruder and evaluate various critical stages in such continuous line using amorphous 109 
polymeric binders. Previous research successfully used amorphous polymers as carriers in 110 
solid dispersions prepared by continuous hot-melt extrusion for downstream processing 111 
towards tablets (Grymonpré et al., 2017a, 2017b). The high milling efficiency and excellent 112 
tableting properties of these polymers suggested their use as polymeric binder during TSMG. 113 
In a first part of the study, five amorphous polymers were screened with two model drugs for 114 
their potential as polymeric binder. Afterwards, a quality-by-design (QbD) approach was 115 
implemented to thoroughly understand the critical process parameters (CPP) during TSMG 116 
and to elucidate the impact of process and formulation parameters on the critical quality 117 
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attributes (CQA) of granules and tablets during continuous manufacturing of high drug-loaded 118 
melt granules.   119 
2.    MATERIALS  120 
Three amorphous polymers were selected from a previously established polymer database for 121 
hot-melt extrusion/tableting (Grymonpré et al., 2017b). Kollidon® VA64 (VA64) and Soluplus® 122 
(SOL) were kindly donated by BASF (Ludwigshafen, Germany), while Eudragit® EPO (EPO) 123 
was provided by Evonik (Darmstadt, Germany). Two HPMC-grades developed for hot-melt 124 
extrusion (HME) (AffinisolTM) with varying molecular weight were donated by DOW (Bomlitz, 125 
Germany): 15 LV and 4M having a low and high molecular weight, respectively. 126 
Acetaminophen (APAP, Mallinckrodt, St. Louis, USA) and hydrochlorothiazide (HCT, UTAG, 127 
Amsterdam, The Netherlands) were used as model drugs for melt granulation based on their 128 
different melting point (171 and 272 °C for APAP and HCT, respectively) which might reflect in 129 
their behaviour during melt granulation. All raw materials and their characteristics are listed in 130 
Table 1.  131 
3. METHODS 132 
3.1. Continuous twin-screw melt granulation  133 
This research paper intended to introduce a concept for implementation of TSMG into a 134 
continuous tablet manufacturing line by combining mixing, TSMG, milling and compression. 135 
Fig. 1 gives a schematic overview of the process-flow and the possible integration of the 136 
various stages in a continuous manufacturing line. The feeding and continuous mixing stage 137 
has been thoroughly investigated and evaluated at our department by Van Snick et al. for a 138 
continuous direct compression line (Van Snick et al., 2017a, 2017b). Therefore, this research 139 
paper mainly focused on the later stages of the continuous concept with TSMG being the first 140 
unit following the feeding/mixing stage. 141 
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3.1.1. Blending and gravimetric feeding  142 
 143 
Before blending the active pharmaceutical ingredient (API) and polymer, the neat API was 144 
milled (Quadro® U5, Waterloo, Canada) using a round arm impeller at 900 rpm with a 1395-145 
micron screen to break up possible powder lumps. Afterwards, blends were prepared for both 146 
model drugs with all amorphous polymers using a tumbling mixer (W.A. Bachofen, Basel, 147 
Switzerland) for 10 min at 15 rpm. These blends were gravimetrically fed to the granulation 148 
unit using a DD Flexwall gravimetric feeder (Brabender Technology, Germany). 149 
3.1.2. Twin-screw melt granulation 150 
 151 
A co-rotating intermeshing twin-screw extruder (Prism Eurolab 16, ThermoFischer Scientific, 152 
Karlsruhe, Germany) was used as granulator with a barrel length of 25 L/D, where L is the 153 
axial screw length and D the inner bore diameter corresponding to one of the screws. The 154 
screw configuration was identical for all experiments, with 2 mixing zones in the third and fifth 155 
segment, each consisting of 6 kneading discs at 60° stagger angle in reversed direction and a 156 
screw-mixing element at the end of each screw intended for break-up of potentially large melt-157 
granule lumps. The granulation barrel is divided into 6 segments (T1-6) which can be 158 
heated/cooled separately. The temperature at the end of the barrel (T6) was lowered to 40 °C 159 
during all runs in order to cool the granules below the glass transition temperature (Tg) of the 160 
polymers, enabling break up of very large agglomerates by the screw-mixing elements and 161 
avoiding sticking of the granules when leaving the barrel. All other segments in the granulator 162 
(T1-5) were kept constant at the same temperature, except for mixtures with EPO for which the 163 
temperature of the feeding segment (T1) was lowered to 80 °C to prevent feeding obstruction. 164 
The granulator was equipped with a data logging system to monitor the screw torque and barrel 165 
temperature during granulation. Sample collection for evaluation of granule properties before 166 
milling was done at stable granulation conditions, based on the process torque values.  167 
3.1.3. Milling  168 
 169 
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After granulation the granules were manually transferred to a Quadro® Comil® (U10, 170 
Quadro®, Ontario, Canada).  Milling was performed with a square impeller at 300 rpm, forcing 171 
the granules through a 1000 m grater screen.  172 
3.1.4. Tableting  173 
 174 
All milled formulations and their physical mixtures (PM) were compressed to tablets on a rotary 175 
tablet press (MODULTM P, GEA Pharma Systems, Halle, Belgium) equipped with cylindrical 176 
flat-faced Euro B punches of 10 mm diameter and an overfill cam of 16 mm. Tablets (250  5 177 
mg) were compressed on 7 different main compaction pressures: 65, 130, 190, 255, 320, 380 178 
and 510 MPa without the use of a pre-compression step at a turret speed of 5 rpm. All tablets 179 
were analysed for ‘out-of-die’ properties (tablet strength, dimensions and mass) immediately 180 
after ejection. Punch deformation at each compaction pressure was calculated and corrected 181 
for during this study. In-die measurements of the compaction properties was performed by 182 
linear variable displacement transducers (LVDT) incorporated inside the turret and clamped 183 
onto one pair of punches, enabling the monitoring of punch stroke movements during a 184 
compression cycle (GEA Pharma Systems, Halle, Belgium). Calibration was performed prior 185 
to processing each formulation, by interpolating the output voltage of the sensor to physical 186 
values during static measurements. A wireless transmission system continuously transmitted 187 
the data from these sensors to a data acquisition and analysis system (CDAAS™, GEA Pharma 188 
Systems, Halle, Belgium).   189 
 190 
3.2. Polymer screening   191 
Physical mixtures with an API-to-polymer ratio of 85/15 (w/w %) were prepared for screening 192 
of the various amorphous polymers as binders in TSMG at fixed material throughput (0.350 193 
kg/h) and screw speed (150 rpm). The granulation temperatures needed for each formulation 194 
are listed in Table 2. These values represent the minimal granulation temperature needed for 195 
each formulation at a certain screw speed and throughput to ensure granulation.   196 
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 197 
3.3. QbD approach for HCT 198 
Design of experiments (DOE) was applied to evaluate the critical process parameters during 199 
continuous TSMG and tableting. A 31-experiment D-optimal design was developed to evaluate 200 
the influence of process parameters: T1 (80°C), T2-5 (160-200 °C), T6 (40 °C), screw speed 201 
(100-200 rpm), throughput (0.200-0.500 kg/h) together with formulation parameters: polymer 202 
type (SOL, EPO, VA64) and binder concentration (15-25 %) on the CQA of granules and 203 
tablets containing HCT. Six centerpoints (two for each polymer type) were included to evaluate 204 
the model reproducibility. In between each experimental run, the granulation unit (i.e. 205 
gravimetric feeder, barrel, screws and co-mill) were cleaned. The results were analysed using 206 
MODDE 10.1 software (Umetrics, Umeå, Sweden). Multiple linear regression (MLR) was used 207 
for calculation of the regression models for each response, whereas all factors were scaled 208 
and centered making the regression coefficients comparable for the different factors. 95% 209 
confidence intervals were calculated for all regression coefficients in order to evaluate if factors 210 
or factor interactions were significant (i.e. 95% confidence interval of the corresponding 211 
regression coefficient not including zero).  212 
 213 
3.4. Evaluation of the TSMG process  214 
 During the granulation process, the torque on the screws was monitored and based on 215 
these values, granule sampling was started after initial torque stabilization. A reading of 100 216 
% corresponded to the maximum allowable torque of 12 Nm. Prior to each run, the friction 217 
torque was determined by running the extruder with screws attached and the barrel empty at 218 
the specific conditions. This friction torque was subtracted from the total recorded torque to 219 
obtain the net torque (Godavarti and Karwe, 1997). The time necessary for each run to reach 220 
torque stabilization was recorded and an evaluation of the variation in torque over the running 221 
time was performed after reaching torque stabilization for each experiment:  222 
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                                                    T/t	ሺ%/minሻ	ൌ ்೐೙೏ି்ೄ௧ 	                                               (1) 223 
where Tend and TS represent the net torque at the end of the granulation experiment and the 224 
initial stable torque value of the experiment, respectively, over the total granulation time starting 225 
from initial torque stabilization (t).   226 
 227 
3.5. Raw material and granule characterization 228 
3.5.1. Solid state characterization   229 
 230 
Thermogravimetric analysis (TGA 2950, TA instruments, Leatherhead, UK) was conducted on 231 
all polymers and drugs to investigate their thermal stability. Samples ( 15 mg) were heated 232 
up to 600 °C after equilibration at 25 °C using a heating rate of 10 °C/min.  233 
Differential scanning calorimetry (DSC, Q2000, TA Instruments, Leatherhead, UK) was used 234 
for raw material screening and comparing PM before and after granulation based on the Tg, 235 
Tm and melting enthalpy.  The DSC-device is equipped with a refrigerated cooling system and 236 
the cell was purged with dry nitrogen at a flow rate of 50 ml/min. A heating rate of 10 °C/min 237 
was used during 3 cycles (heat, cool, heat) from 0 °C to 200 °C for APAP-formulations and 0 238 
°C to 290 °C for HCT-formulations of around 10 mg weighed in T-zero pans. Crystallinity Xc 239 
(%) of APAP in the granules was calculated based on the enthalpy of fusion of APAP in the 240 
corresponding physical mixture (PM) using following equation:    241 
   242 
 Xc	ሺ%ሻ = ( ∆Hf∆Hf* ) x 100             (2) 243 
with ∆Hf and ∆Hf* representing the enthalpy of fusion (J/g) for APAP in granules and PM, 244 
respectively.  245 
 246 
 247 
X-ray Diffraction (XRD) was performed on both PM and melt granules (MG). A D5000 CU K 248 
diffractor (= 0.154 nm) (Siemens, Karlsruhe, Germany) with a voltage of 40 V in the angular 249 
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range of 10° < 2 < 20° was used in a step scan mode (step width = 0.02°, counting time = 1 250 
s/step). 251 
3.5.2. Moisture content  252 
Loss on drying (LOD) was performed (n=3) on the raw materials, physical mixtures and 253 
granules before tabletting to determine residual moisture content using a Mettler LP16 254 
moisture analyser, including an infrared dryer and a Mettler PM460 balance (Mettler-Toledo, 255 
Zaventem, Belgium). Approximately 1 g of sample was dried at 105 °C until the rate of change 256 
was less than 0.1 w/w % over 30 s.  257 
3.5.3. True density  258 
Helium pycnometry (AccuPyc 1330, Micromeritics, Norcross, USA) was performed on raw 259 
materials, PM, milled and unmilled granules in order to determine the true densities (g/ml). 260 
The number of purges was set to 10 with an equilibration rate of 0.00050 psig/min. Calibration 261 
was performed between the formulations.  262 
3.5.4. Particle size and shape analysis  263 
For the raw materials, particle size distribution (PSD) was determined (n=3) by laser diffraction 264 
(Mastersizer-S long bench, Malvern Instruments, Malvern, UK) via dry dispersion method in 265 
volumetrical distribution mode using a 300 RF lens combined with a dry powder feeder at 266 
feeding rate of 3.0 G and jet pressure of 4.0 bar (Malvern Instruments, Malvern, UK). Analysis 267 
of the granule size before and after milling was done via dynamic image analysis using the 268 
QICPICTM system (Sympatec, Clausthal-Zellerfeld, Germany) equipped with a vibrating feeder 269 
system (VIBRI/LTM) for gravimetrical addition of the granules. Approximately 20 g of sample 270 
was analysed to determine the median granule size (d50) as the equivalent projected circle 271 
diameter, median aspect ratio (AR) and median sphericity (S) by using Windox 5 Software 272 
(Sympathec, Clausthal-Zellerfeld, Germany). All calculations were volume based. The aspect 273 
ratio is defined as the ratio of the maximal Feret diameter to the diameter orthogonal to it, and 274 
sphericity is the ratio of the perimeter of the equivalent circle to the real perimeter. Perfectly 275 
regular and spherical particles have AR and S values of 1. The amount of fines and oversized 276 
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granules were defined as the fractions <150 µm and >1000 µm, respectively, whereas the yield 277 
of the process was defined as the percentage of granules between 150 µm and 1000 µm. The 278 
milling efficiency (%) of the co-mill for all formulations was determined by calculating the 279 
difference between % oversized granules before and after milling normalized by the initial % 280 
oversized granules.    281 
3.5.5. Granule friability  282 
Granule friability was determined in duplicate using a friabilator (PTF E Pharma Test, Hainburg, 283 
Germany). 10 g of granules (Iwt) together with 200 glass beads (d=4mm) were rotated in an 284 
abrasion wheel for 10 min at a speed of 25 rpm, subjecting them to falling shocks.  285 
Prior to the analysis, the fraction < 250 µm was removed by sieving to assure similar starting 286 
conditions. Afterwards, the glass beads were removed and the weight retained on a 250 mm 287 
sieve (Fwt) was determined.  The friability was calculated using equation (3)  288 
            Friability	ሺ%ሻ	ൌ	 ሺIwt	‐	Fw	tሻIwt 	ݔ	100	                                        (3) 289 
3.5.6. Rheology 290 
Rheological analyses were performed on polymeric binders using a Thermo Scientific HAAKE 291 
MARS III (Modular Advanced Rheometer System, Thermo Fisher Scientific, Karlsruhe, 292 
Germany) with a parallel plate (d=20 mm) as geometrical set-up in order to evaluate the 293 
viscoelastic behaviour of the binders at various angular frequencies. At first, an amplitude 294 
sweep was performed on the samples to determine the linear viscoelastic region. Oscillation 295 
frequency sweeps were performed at 160 °C by increasing the angular frequency from 0.1 to 296 
100 ° Hz using an applied strain of 1 %. 297 
 298 
 299 
 300 
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3.6. Tablet evaluation 301 
3.6.1 Out-of-die tablet properties 302 
Tablet diametral tensile strength was calculated using the equation described by Fell and 303 
Newton (1968):    304 
          Tablet	Tensile	Strength	ሺσt	ሻ	ൌ	 ଶ௉గ஽௧                      (4) 305 
where P, D and t denotes tablet diametral breaking force (N), tablet diameter (mm) and tablet 306 
thickness (mm), respectively, which are determined using a combitester (Multitest 50, Dr. 307 
Schleuniger, Sotax, Basel, Switzerland).  308 
 309 
 310 
In order to determine the porosity of the compacts following equation is used:  311 
     Tablet	Porosity	ൌ	1 െ	 	ఘೌ೛೛	ఘ೟ೝೠ೐                        (5) 312 
where ρapp and ρtrue denote the apparent and true density (g/ml), respectively. The latter was 313 
measured using helium pycnometry while the apparent density was calculated by dividing the 314 
tablet mass by the volume of the tablet.  315 
Compactibility of the formulations was assessed by plotting tablet tensile strength in function 316 
of tablet porosity, a relationship that was described by Ryshkewitch:  317 
      318 
            	ߪ௧ ൌ 	ߪ଴	݁ି௕௉           (6) 319 
where σt and ߪ଴ denotes the tablet tensile strength (MPa) and limiting tablet tensile strength at 320 
zero porosity (MPa), respectively, b is an empirical constant and P denotes the tablet porosity 321 
(Ryshkewitch, 1953). 322 
3.6.2. In-die tablet properties 323 
 324 
Energy plots (i.e. force-displacement curves) were recorded during the compression cycles 325 
which enabled the calculation of the energy consumption or dissipation at each phase from the 326 
area under the curve (Michaut et al., 2010):       327 
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       ܧ ൌ 	׬ ܨ	݄݀          (7) 328 
where F denotes the compression force (kN) and h the punch separation (mm). All energies 329 
are normalised by taking the compact mass into account to allow comparison between the 330 
different formulations. Resulting energies are used for calculating two specific compaction 331 
properties:   332 
‐ A plasticity factor (PF) which represents the energy of compaction used for plastic 333 
deformation and fragmentation:  334 
    ܲܨ	ሺ%ሻ ൌ 	 ௡௘௧	௘௡௘௥௚௬௧௢௧௔௟	௘௡௘௥௚௬ 	ݔ	100                  (8) 335 
‐ In-die elastic recovery (IER) which represents the elasticity of a material:  336 
    ܫܧܴ	ሺ%ሻ ൌ 	 ்೏ି ೎்
೎்
	ݔ	100         (9) 337 
where Td and Tc represents the punch separation after decompression and the minimal 338 
punch separation during compression, respectively.   339 
All calculations for in-line measuring the compaction properties were done using the CDAAS 340 
software (GEA Pharma Systems, Halle, Belgium) on at least 3 compacts for each formulation. 341 
Using the in-die data of the CDAAS system, Heckel analysis was performed on all 342 
formulations. The theory of Shapiro-Konopicky-Heckel is based on following equation (Heckel, 343 
1961):  344 
     ݈݊	 ଵா ൌ ܭܲ ൅ ܣ                   (10) 345 
where E is the porosity of the powder bed at a compaction pressure P, K is the slope of the 346 
linear part of the plot (with the best R2 fit) and A is the Y intercept with the linear part of the 347 
plot. The mean Heckel yield pressures (Py) are given by the reciprocal values K, while the 348 
intercept of both the linear part of the plot (A) and the non-linear part (I) are used to calculate 349 
Da, DI.  350 
   Da	ሺIሻ	ൌ	1‐	݁ି஺	ሺூሻ		 	 	 	 	 			(11)	351 
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The difference between Da and DI denotes Db, a fragmentation factor, which describes the 352 
reduction in volume due to rearrangement of the particles since A is said to reflect low pressure 353 
densification by interparticulate motion (Tarlier et al., 2015).  354 
           Db	ൌ	Da	–	DI		 	 	 	 	 					(12) 355 
3.7. Multivariate data analysis 356 
Principal component analysis (PCA) was executed on the relevant compaction data in 357 
order to classify the DOE-experimental runs according to their compaction behaviour using the 358 
multivariate data analysing software SIMCA 13.0.3 (Umetrics, Umeå, Sweden). The dataset 359 
consisted of 31-rows (i.e. the DOE-experiments) for 5 variables (i.e. PF, PF-slope, IER, Db and 360 
Py).  PCA is a multivariate projection method which extracts and displays the variation in the 361 
data set (Pieters et al., 2013). The data was pre-processed by unit variate scaling and centered 362 
in order to balance the weight of each variable. 363 
 364 
 365 
 366 
 367 
 368 
 369 
 370 
 371 
 372 
 373 
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4.    RESULTS AND DISCUSSION 374 
4.1. Polymer screening for TSMG 375 
4.1.1. TSMG-process  376 
 377 
Preliminary experiments were performed in order to determine the minimal polymer 378 
concentration required to prepare granules. Overall, a binder concentration of 15 % resulted 379 
in good granules for all polymer types in combination with APAP and HCT, which was therefore 380 
selected as binder concentration during the polymer screening (Table 2). 381 
TGA indicated that all formulations were thermally stable during the TSMG experiments, as 382 
the degradation temperatures of the components are higher than the used processing 383 
temperatures (Table 1). The processing temperatures at which granulation occurred depended 384 
on the polymeric binder: both Affinisol™-grades needed substantially higher temperatures 385 
compared to the other amorphous polymers (Table 2). This was linked to the high complex 386 
viscosities of these polymers in low shear regions (Gupta et al., 2016). Although good granules 387 
were produced at those elevated temperatures, the application of Affinisol™-grades as 388 
polymeric binder in TSMG is expected to be limited to a few active pharmaceutical ingredients 389 
which are thermally stable at temperatures over 200 °C.  390 
During this study, it was important to verify if the granulation process induced polymorphisms 391 
or changes in the physical state of the drug, especially for APAP-formulations since some 392 
processing temperatures exceeded Tm of the component and it has been reported that 393 
extrusion of APAP with amorphous polymers (SOL and VA64) at elevated temperatures 394 
induced polymeric transformation of APAP from the most stable monoclinic Form I to a 395 
orthorhombic Form II with minor stability (Maniruzzaman et al., 2014). Changes in the 396 
crystalline structure of a molecule can lead to significant changes in the mechanical properties 397 
of the molecule and could therefore confound the tableting results if not considered 398 
(Grymonpré et al., 2016). The orthorhombic form of APAP exhibits more fragmentation and 399 
plastic deformation under compression leading to far better tabletability compared to the 400 
 
 
16
monoclinic form, caused by sliding planes present in the orthorhombic form (Joiris et al., 1998). 401 
Both XRD and DSC results confirmed the monoclinic form in the starting material, with distinct 402 
crystalline peaks in the diffractogram at 2 values of 12.12°, 13.88°, 15.52°, 18.20°, 20.42°, 403 
23.55°, 24.36° and 26.58° and a sharp melting endotherm at 170.6 °C in the thermograms. 404 
The transition from polymorphic Form I to II described by Maniruzzaman et al. during extrusion 405 
was characterized by a shift of the peak at 24.36° 2 to a higher intensity peak at 24.03° 2 406 
(Maniruzzaman et al., 2014) which was not noticed comparing the APAP physical mixtures 407 
before and after TSMG. Moreover, the thermograms of both formulations showed similar sharp 408 
melting point (± 171 °C) highlighting the resistance of the formulation to polymorphic transition 409 
(Form I to II) ruling out possible confounding of the tableting results. Due to the design of the 410 
equipment used for continuous melt granulation, material residence time is reduced 411 
significantly (i.e. several seconds) compared to traditional batch processing (Monteyne et al., 412 
2016a). Therefore, it was assumed that even at processing temperatures exceeding Tm it is 413 
unlikely that complete melting of APAP occurred especially since the drug load of the melt-414 
granules was high. However, the process conditions during TSMG affected the crystallinity of 415 
APAP after processing (Table 2). 96.0-98.9 % of APAP was in the crystalline state processed 416 
at temperatures below Tm, while only 87.2%-88.5% crystalline APAP was detected in 417 
combination with the Affinisol™ binders as these were processed at temperatures exceeding 418 
Tm of the drug. This lower fraction of crystalline APAP in the Affinisol™ formulations was 419 
probably not only induced by melting of APAP, but amplified by the higher miscibility of APAP 420 
in these binders, linked to the lower differences in solubility parameters (∆δ) between API-421 
polymer (Table 2). Greenhalgh et al. investigated trends in solubility parameters of various 422 
API-carrier systems and postulated that compounds with a ∆δ<7.0 MPa0.5 were likely to be 423 
miscible, but likely to be immiscible when ∆δ>10 MPa0.5(Greenhalgh et al., 1999). Three-424 
dimensional Hansen’s solubility parameters calculated by the group contribution methods 425 
(Fedors, 1974; Van Krevelen and Hoftyzer, 1976) were obtained from literature and used to 426 
estimate the miscibility of API-polymer (Table 1). Regarding the HCT-formulations, no 427 
polymorphic transition or change in physical state during TSMG was expected since the 428 
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granulation temperatures were far below Tm of HCT and the high ∆δ values between HCT and 429 
the polymeric binders (>10 MPa0.5) were observed. 430 
   431 
4.1.2. Granule properties  432 
 433 
From a continuous manufacturing perspective, ideal granule properties include low moisture 434 
content (<1 %), high granule sphericity, small fraction of fines (<10 %) after milling and a high 435 
granule yield in the desired size-fraction for tabletting (Meena et al., 2017). In the proposed 436 
manufacturing line (Fig.1), the target PSD of granules was in the 150-1000 µm range to enable 437 
an efficient powder transfer towards the rotary tablet press and to avoid segregation when 438 
adding extragranular components before tableting. In this respect, the formulations were 439 
evaluated on binder efficiency (reflected in the % fines of the unmilled granules) and their 440 
milling efficiency since the oversized granule fraction needed to be sufficiently reduced by 441 
milling (<1000 µm) without creating an excess of fines.      442 
For all formulations, granule moisture content was < 1 % and the granule sphericity was 443 
between 0.81-0.85, indicating regularly shaped granules with good flow properties, ideal 444 
conditions for further downstream processing in the continuous manufacturing line (Meena et 445 
al., 2017). Table 3 provides an overview of the granule properties for both unmilled and milled 446 
fractions. The fines fraction of the unmilled samples indicated that granules of most 447 
formulations had a high initial strength (i.e. <1% fines), except for HCT combined with Affinisol™ 448 
(H-4M, H-15LV). This might be due to a difference in granulation mechanism, as the 449 
opportunity for interaction between HCT and the Affinisol™-grades was higher compared to the 450 
other polymeric binders, based on the ∆δ values (Table 2). The correlation between API/binder 451 
miscibility and granulation mechanism (i.e. binder distribution) is described by Monteyne et al., 452 
which could be related to the different initial granule strengths observed in the present study 453 
(Monteyne et al., 2016a). 454 
In this study, process settings and screw configurations were deliberately not adapted to 455 
generate a low initial oversize fraction which resulted in a high fraction of oversized (unmilled) 456 
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granules (Table 3). This approach enabled an evaluation of the co-mill unit on its ability to 457 
eliminate potential deviations in granule PSD after the TSMG process. A good control of the 458 
PSD is crucial for both downstreaming or end-product quality and therefore an efficient milling-459 
unit is indispensable in the proposed manufacturing line. To guarantee a high yield of the 460 
process, deviations in the granule PSD at the granulation unit during continuous processing 461 
can be bypassed with the co-mill unit if the formulation has a high milling efficiency.   462 
This was the case when using amorphous polymers as binder in TSMG for both model drugs 463 
with milling efficiencies of minimal 92.2 % (Table 3). Previous research stated the excellent 464 
milling properties of these amorphous polymers when used as carriers for solid dispersions 465 
based on their brittle behaviour (Grymonpré et al., 2017b). The highest efficiencies were 466 
reached when using EPO and the Affinisol™-grades as binder, however milling of these 467 
granules resulted in more fines compared to granules formulated with SOL and VA64 as 468 
binder, indicating slightly lower resistance towards the impeller impact during milling. The 469 
importance of the milling process after granulation is clearly reflected in Fig. 2, where the yield 470 
of granules for further downstreaming is plotted in function of the formulation. Milling increased 471 
the yield to at least 89.6 % for all formulations by breaking up the oversized granules.  472 
When focussing on the desired granule properties, all screened amorphous polymers showed 473 
good potential as TSMG-binder when processing APAP and HCT. In this context, SOL and 474 
VA64 could be recommended as polymeric binders since they combine a high milling efficiency 475 
with a higher resistance to fine formation.  476 
 477 
 478 
 479 
 480 
 481 
 482 
 483 
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4.1.3. Tablet properties  484 
 485 
The tableting behaviour of the granules was evaluated in comparison to the physical mixtures 486 
of the various formulations by plotting the tabletability (Fig. 3). The latter describes the ability 487 
of a material to form compacts with a certain tensile strength (TS) in function of the compaction 488 
pressure exerted on the powder bed. For melt granules of both APAP and HCT formulations, 489 
significantly higher tabletabilities were noticed in comparison with their physical mixtures. 490 
Improvement of the tableting behaviour of a drug by co-processing with excipients has been 491 
reported previously in literature. Shi et al. reported a co-processing method for improving the 492 
tabletability of acetaminophen by crystal coating with hydroxypropyl cellulose (HPC) (Shi and 493 
Sun, 2011). Lakshman et al. formulated melt granules of metformin hydrochloride with 494 
increased compactibility using HPC as binder (Lakshman et al., 2011), while recent work by 495 
Batra et al. confirmed the potential of polymeric binders in melt-granulation to improve the 496 
compactibility of drugs (Batra et al., 2017). In general, the underlying mechanism for 497 
improvement of the tabletability is the same for all cited examples. The poorly compactible 498 
drug crystals are coated with a layer of polymer, which displayed more plastic and/or brittle 499 
behaviour, creating more interparticulate contacts (i.e. higher bonding area) and forming 500 
stronger bondings under compaction. For the present study, it is postulated that the polymeric 501 
binder behaved as a separate phase which distributed over the drug particles when softened 502 
during TSMG, as was reported by Lakshman et al. and confirmed by Monteyne et al. for 503 
immiscible drug-binder blends (Lakshman et al., 2011; Monteyne et al., 2016a).  504 
Only minor differences were noticed in tablet TS between melt-granules of both drug 505 
formulations while the EPO-formulations had higher bonding strengths at zero porosity when 506 
analysing the compactibility plots (Fig. 4). This could be explained by the tendency of EPO to 507 
experience a more extensive elastic recovery during decompression, possibly disrupting some 508 
previously formed interparticulate bondings. When comparing the bonding strengths at zero 509 
porosity (Fig. 4) for HCT-melt granules, it showed slightly higher tablet tensile strengths at zero 510 
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porosity compared to APAP-melt granules for all screened polymeric binders. This was 511 
assigned to the better initial tabletability of neat HCT compared to APAP (Fig. 3). 512 
 513 
4.2. QbD approach for HCT  514 
HCT was selected as model drug for the QbD melt-granulation approach based on 515 
experimental knowledge obtained during the polymer screening. HCT-formulations exhibited 516 
better feeding performances enabling good throughput variations as the true density of HCT is 517 
significantly higher compared to APAP (Table 1).  518 
Both Affinisol™-grades were excluded in this part of the study, as excessive temperatures were 519 
needed to initiate granulation with all model drugs (Table 2) and therefore have less potential 520 
as polymeric binder in TSMG from our opinion. An overview of all individual experiments of the 521 
DOE is provided in Table 4.  522 
4.2.1. Evaluation of the TSMG-process  523 
 524 
When granulation trials were started, the process torque showed large fluctuations up to a 525 
point where the torque readings were stable. This phenomenon was attributed to layering of 526 
the barrel wall and screws (Vercruysse et al., 2012). For the majority of the DOE-runs, the time 527 
needed for stabilizing the torque was < 10 min with a remarkable reduction at higher material 528 
throughput.  529 
The average torque values after initial torque stabilization were influenced by both formulation 530 
and process factors of the DOE. Using VA64 as polymeric binder resulted in significantly higher 531 
basal torque values (i.e. the stabilized torque value at the start of the sampling period), 532 
whereas for EPO-formulations the response was remarkably lower. This was correlated with 533 
the Tg of the binders (Table 1) as the melt viscosity of VA64-formulations during processing 534 
was higher compared to EPO-formulations at similar granulation conditions, especially when 535 
incorporating a higher binder concentration (Grymonpré et al., 2017b).  536 
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Softening of the polymer is required to lower the melt viscosity of a formulation as reflected by 537 
the influence of barrel temperature and screw speed on the basal torque values: while a direct 538 
impact of temperature was observed, a higher screw speed reduced the melt viscosity via 539 
shear thinning of the binder (Bochmann et al., 2017; Deshmukh et al., 2016; Villmow et al., 540 
2010). The effect of shear rate on the binders was studied by measuring the complex viscosity 541 
(*) as function of angular frequency (Fig. 5) at a temperature of 160 °C. During granulation, 542 
materials undergo high shear due to the rotating screws. A reduction of the complex viscosity 543 
at higher angular frequency is indicative for shear thinning (Gupta et al., 2016), which occurred 544 
for all binders (Fig. 5). When comparing the polymeric binders, a strong difference in complex 545 
viscosity was observed, VA64 having the highest viscosity and EPO a rather low viscosity. 546 
Based on Fig. 5 it is evident that VA 64 and SOL were more prone to shear thinning compared 547 
to EPO as the onset of the reduction in complex viscosity already occurred at lower angular 548 
frequencies. However, the impact of shear thinning was expected to be more substantial for 549 
EPO-formulations (despite the lower onset of shear thinning) since the complex viscosity 550 
values were below 1000 Pa.S and hence the binder behaved fluid-like during melt granulation 551 
at high shear conditions (Gupta et al., 2015). 552 
At higher throughputs, more energy input is required in order to reduce the melt viscosity of 553 
the formulations at similar granulation conditions, resulting in higher basal torque levels. In a 554 
continuous manufacturing line, it is crucial that all processing steps are run in a robust and 555 
efficient way. When focussing on the granulation stage, barrel obstruction due to torque 556 
overload must therefore be avoided. As can be seen in Fig. 6 for the centerpoint runs (i.e. at 557 
similar granulation settings) with the three polymeric binders, the torque increased from the 558 
basal torque value to higher levels in function of sampling time.   559 
As the VA64-formulation showed a much higher basal torque value, this tendency resulted in 560 
obstruction of the granulation unit due to torque overload. However, Fig. 6 represents only the 561 
torque profile at specific granulation conditions. By including the torque variation over time as 562 
response in the DOE, in-depth knowledge was gained on the impact of formulation and process 563 
factors on this response and how to reduce the risk of granulation obstruction for challenging 564 
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formulations. Fig. 7 shows the coefficient plot of the latter response, displaying the regression 565 
coefficients of each factor and factor interaction. The regression coefficient of a specific factor 566 
represents the quantitative change in response value when this factor is increased from its 567 
average to its high level, keeping all other factors at their average value.  568 
VA 64-formulations showed a significantly higher torque increase in function of granulation 569 
time which was in line with the tendency observed in Fig. 6. Although the risk of obstruction 570 
during melt granulation was higher using VA64-containig formulations, the observed 571 
interactions between polymer type and granulation settings allowed to adjust granulation 572 
settings during TSMG in order to reduce this risk.  573 
Important interactions with the polymer type were noticed for screw speed and throughput, 574 
from analysing the interaction plots in Fig. 8. Precaution should be taken when increasing the 575 
screw speed for EPO-formulations, as the resulting shear thinning effect could result in a more 576 
extensive binder distribution inside the barrel and hence increasing torque levels over longer 577 
time (Fig. 5). The challenging VA 64 formulations (i.e. polymeric binder with high Tg) showed 578 
a significant decrease in torque over time when processed at high screw speed and low 579 
throughput. At those granulation settings, the use of VA 64 as polymeric binder will result in 580 
successful granulation without barrel obstruction during a continuous granulation process. 581 
Regarding continuous processing, SOL would be the most deliberate option as binder for 582 
TSMG since this polymer is less prone for torque increase during longer granulation trials, 583 
independent of the process settings (Fig. 8). A more extensive self-wiping effect of the screws 584 
was noticed when using SOL-formulations, explaining the torque decrease over time.  Fig. 7 585 
revealed an interaction between binder concentration and barrel temperature. It is 586 
recommended when processing formulations with higher percentage of binder and comparable 587 
thermal properties, to increase the granulation temperatures in order to minimize the risk for 588 
barrel obstruction.    589 
 590 
 591 
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4.2.2. Evaluation of melt granule quality 592 
 593 
During the polymer screening, it was noticed that a high amount of oversized granules (>1000 594 
µm) were produced with all polymeric binders and the importance of an efficient milling step 595 
was highlighted in order to generate a high granule yield (150-1000 µm) for downstreaming 596 
into tablets. The percentage of initial oversized granules was high for all polymeric binders (62-597 
98 %). No statistical significant correlations between % oversized unmilled granules and 598 
formulation or process factors were detected, except for an interaction between polymer type 599 
and screw speed (Fig. 9). The % of oversized granules for VA64-formulations was significantly 600 
decreased by granulation at higher screw speed. This was explained by the more brittle 601 
behaviour of VA64-formulations at the end of the granulation barrel (i.e. T6=40°C) as the 602 
temperature difference with the Tg of VA64 is high (∆T=68°C) compared to SOL (∆T=24°C) 603 
and especially EPO (∆T=13°C).  604 
 605 
The percentage of fines leaving the granulation barrel was low (<1.7%) for all runs, indicating 606 
a high robustness of the TSMG-process for this response within the DOE- granulation settings.  607 
For all formulations, highly efficient break-up of the oversized granule fraction occurred as 608 
evidenced by the milling efficiency (Fig. 10, A). A slight reduction in this response was noticed 609 
with increasing percentages of binder, however the milling efficiency of all runs remained high 610 
(> 87 %). The fines induced by milling was not excessive (Fig. 10, B), with the highest amount 611 
of fines reached in the design still being an acceptable 5.98%. Overall, the co-milling unit in 612 
this line performed with a high efficiency for melt-granules of amorphous polymeric binders 613 
resulting in high yield values (>85.6 %) independent of the TSMG process-settings (Fig. 10, 614 
C). Granule friability of the melt-granules was very low (< 9 %) with all polymeric binders, 615 
independent of the binder concentration or TSMG process settings (Fig. 10, D). These low 616 
friability values indicated a high granule strength, which make these melt granules extremely 617 
suitable for downstream processing. Melt-granules with SOL as polymeric binder showed the 618 
lowest friability (< 4%).  619 
 
 
24
4.2.3. Evaluation of the tableting behaviour 620 
 621 
The beneficial effects of formulating HCT as melt granules with polymeric binders on the 622 
tabletability was described earlier in the section polymer screening. A more in-depth evaluation 623 
of the tableting behaviour for all experimental runs was done by in-line monitoring of the 624 
compaction properties at the tableting stage (Table 5). PCA was a useful tool to summarize 625 
the behaviour under compaction of the melt granules in a comprehensive way, as represented 626 
in the bi-plot at Fig. 11. The two principal components (PC) in the current model accounted for 627 
88.6 % of the total variance in the dataset with PC1 and PC2 comprising 78.0 % and 10.6 %, 628 
respectively. The loadings indicated that PC1 (x-direction) differentiated mainly between the 629 
deformation mechanisms under compression.  The plastic deformation potential (i.e. PF and 630 
Py) was anti-correlated with the elastic recovery (i.e. IER) and the PF slope. PC2 (y-direction) 631 
captured the fragmentary behaviour of the materials (i.e. Db) while being correlated with PF 632 
and Py of PC1.  633 
Formulations which underwent more extensive plastic deformation during compression are 634 
located left of the origin in PC1- direction (high PF and PY), which was the case for melt granules 635 
with SOL (red circles) and VA64 (orange boxes) as polymeric binders. A clear cluster was seen 636 
for the experimental runs with EPO (blue triangles) as polymeric binder, located right of the 637 
origin in PC1-direction, indicative of higher in-die elastic recovery after compression (high IER 638 
and low Py) especially for runs 8-11 which represent EPO-concentrations of 25 % (Patel et al., 639 
2007). Moreover, the formulations which deform more plastically (i.e. SOL and VA64) have a 640 
higher tendency of initial fragmentation under compression (high Db) in contrast to EPO-641 
formulations. These results were in line with earlier research on compression with amorphous 642 
polymers, highlighting the higher elastic deformability and low fragmentary behaviour of EPO 643 
(Grymonpré et al., 2017b). For VA64 and EPO-formulations, it was noticed that the contribution 644 
of PC2 was relatively small and no distinction could be made in function of process settings 645 
and binder concentration. However, this was not the case for SOL-formulations as reflected 646 
more specifically by experiment 12 and 19. Run 19 of the DOE differed from run 12 in polymer 647 
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concentration and screw speed (Table 4), with higher % of SOL-binder and screw speed 648 
leading to more fragmentary behaviour of the melt-granules (i.e. Db). This was explained by 649 
the ‘brittle’ behaviour of the polymer itself while higher screw speed during TSMG can lead to 650 
a more extensive polymer distribution on the melt-granules.  651 
When plotting PF in function of the compaction pressures for the formulations, a linear relation 652 
was found (R2 > 0.99). Therefore, the slope of these curves could be used as response to 653 
evaluate the plastic deformation of the formulations at all exerted compaction pressures. 654 
Higher slopes are indicative for less plastic deformation under compaction. Significantly higher 655 
PF-slopes were noticed for EPO-formulations. Melt granules of VA64-fromulations had 656 
significantly lower slopes, highlighting their plastic deformation under compression. These 657 
results explain the positioning of the scores on the bi-plot (Fig. 11) in the direction of PC1.   658 
 659 
 660 
 661 
 662 
 663 
 664 
 665 
 666 
 667 
 668 
 669 
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5.      CONCLUSIONS 676 
Amorphous polymers have a high potential as polymeric binders for TSMG, resulting in melt-677 
granules with extremely low friability whereas the good milling efficiency of these formulations 678 
provide a high granule yield for downstream processing towards tablets with improved 679 
tabletability. One of the most critical stages during continuous TSMG with polymeric binders 680 
was the granulation unit since some experimental runs (with VA64 as polymeric binder) 681 
exhibited a significant torque increase over granulation time eventually resulting in a barrel 682 
obstruction, which was linked to the high Tg of the polymer. However, by fine-tuning the 683 
granulation settings (i.e. screw speed and throughput), this risk was significantly reduced 684 
whereas the use of polymers with lower Tg (i.e. SOL and EPO) guaranteed a more stable 685 
granulation process over time. In similar context, when using higher concentrations of 686 
polymeric binders, it is recommended to increase the granulation temperature in order to 687 
minimize the risk for barrel obstruction. The tableting behaviour under compression is 688 
dependent on the type of polymeric binder, with EPO-formulations exhibiting less 689 
fragmentation and more elastic deformation under compression compared to SOL and VA64-690 
formulations. Overall, this research emphasized that the twin-screw melt granulation process 691 
was very robust regarding the CQA of both high-drug loaded melt granules and their tablets, 692 
which are important features in the concept of continuous manufacturing. Therefore, TSMG 693 
can be considered as a viable processing technique during formulation development of 694 
pharmaceutical oral solid dosage forms. 695 
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